Halaven reimbursed in France, but EU prices reflect austerity and delay
This article was originally published in Scrip
Executive Summary
Eisai's end-of-life breast cancer drug Halaven (eribulin) has won reimbursement in France. The firm has welcomed the news, although the price is not quite what it had hoped for, commented Nick Burgin, Eiasi's European marketing director. Meanwhile, procedural delays in getting the drug to market in Spain and Ireland are dragging on, along with the deepening financial crisis.